Using Phenotype MicroArrays to Determine Culture Conditions That Induce or Repress Toxin Production by Clostridium difficile and Other Microorganisms

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lei, Xiang He ^a   Bochner, Barry R ^a  

^a Biolog Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ARGININE; CARBON; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GLUTAMIC ACID; GLYCINE; GUANOSINE; LEUCINE; METHYLAMINE; NITROGEN; PHOSPHORUS; SULFUR;

ANIMAL CELL; ARTICLE; BACILLUS CEREUS; BACTERIAL STRAIN; BIOTECHNOLOGY; CELL BASED CYTOTOXICITY ASSAY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM SORDELLII; CLOSTRIDIUM TETANI; CONTROLLED STUDY; ESCHERICHIA COLI; LISTERIA INNOCUA; LISTERIA MONOCYTOGENES; MICROARRAY ANALYSIS; MICROBIAL DIVERSITY; MICROORGANISM; NONHUMAN; PATHOGENESIS; PHENOTYPE; QUANTITATIVE ANALYSIS; SHIGELLA DYSENTERIAE; SHIGELLA SONNEI; SPECIES DIFFERENTIATION; TOXIN SYNTHESIS;

BACTERIAL TOXINS; CELL CULTURE TECHNIQUES; CLOSTRIDIUM DIFFICILE; CULTURE MEDIA; CYTOTOXINS; HUMANS; PROTEIN ARRAY ANALYSIS;

EID: 84874280743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056545     Document Type: Article

References (93)

1. Bochner BR, (2003) New technologies to assess genotype-phenotype relationships. Nat Rev Genet 4: 309-314.
2. Bochner BR, Gadzinski P, Panomitros E, (2001) Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res 11: 1246-1255.
3. Bochner BR, (2009) Global phenotypic characterization of bacteria. FEMS Microbiol Rev 33: 191-205.
4. Bochner BR, Siri M, Huang RH, Noble S, Lei XH, et al. (2011) Assay of the multiple energy-producing pathways of mammalian cells. PLoS One 6: e18147.
5. Gardiner DM, Kazan K, Manners JM, (2009) Nutrient profiling reveals potent inducers of trichothecene biosynthesis in Fusarium graminearum. Fungal Genet Biol 46: 604-613.
6. Gardiner DM, Osborne S, Kazan K, Manners JM, (2009) Low pH regulates the production of deoxynivalenol by Fusarium graminearum. Microbiology 155: 3149-3156.
7. Singh MP, (2009) Application of Biolog FF MicroPlate for substrate utilization and metabolite profiling of closely related fungi. J Microbiol Methods 77: 102-108.
8. George WL, Sutter VL, Goldstein EJ, Ludwig SL, Finegold SM, (1978) Aetiology of antimicrobial-agent-associated colitis. Lancet 1: 802-803.
9. Aronsson B, Mollby R, Nord CE, (1981) Occurrence of toxin-producing Clostridium difficile in antibiotic-associated diarrhea in Sweden. Med Microbiol Immunol 170: 27-35.
10. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB, (1978) Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 75: 778-782.
11. Rupnik M, Wilcox MH, Gerding DN, (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526-536.
12. Songer JG, Anderson MA, (2006) Clostridium difficile: an important pathogen of food animals. Anaerobe 12: 1-4.
13. He M, Sebaihia M, Lawley TD, Stabler RA, Dawson LF, et al. (2010) Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci U S A 107: 7527-7532.
14. Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, et al. (2006) Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 188: 7297-7305.
15. Stabler RA, He M, Dawson L, Martin M, Valiente E, et al. (2009) Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10: R102.
16. Stabler RA, Valiente E, Dawson LF, He M, Parkhill J, et al. (2010) In-depth genetic analysis of Clostridium difficile PCR-ribotype 027 strains reveals high genome fluidity including point mutations and inversions. Gut Microbes 1: 269-276.
17. Sebaihia M, Wren BW, Mullany P, Fairweather NF, Minton N, et al. (2006) The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38: 779-786.
18. Warny M, Pepin J, Fang A, Killgore G, Thompson A, et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084.
19. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441.
20. Tae CH, Jung SA, Song HJ, Kim SE, Choi HJ, et al. (2009) The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 24: 520-524.
21. Lim PL, Ling ML, Lee HY, Koh TH, Tan AL, et al. (2011) Isolation of the first three cases of Clostridium difficile polymerase chain reaction ribotype 027 in Singapore. Singapore Med J 52: 361-364.
22. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353: 2442-2449.
23. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, et al. (1995) Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375: 500-503.
24. Gerhard R, Nottrott S, Schoentaube J, Tatge H, Olling A, et al. (2008) Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 57: 765-770.
25. Just I, Fritz G, Aktories K, Giry M, Popoff MR, et al. (1994) Clostridium difficile toxin B acts on the GTP-binding protein Rho. J Biol Chem 269: 10706-10712.
26. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, et al. (1995) The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 270: 13932-13936.
27. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, et al. (2010) The role of toxin A and toxin B in Clostridium difficile infection. Nature 467: 711-713.
28. Czuprynski CJ, Johnson WJ, Balish E, Wilkins T, (1983) Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun 39: 1368-1376.
29. Chang TW, Bartlett JG, Gorbach SL, Onderdonk AB, (1978) Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun 20: 526-529.
30. Knoop FC, (1979) Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin. Infect Immun 23: 31-33.
31. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD, (1985) Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47: 349-352.
32. Bongaerts GP, Lyerly DM, (1994) Role of toxins A and B in the pathogenesis of Clostridium difficile disease. Microb Pathog 17: 1-12.
33. Kyne L, Warny M, Qamar A, Kelly CP, (2000) Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342: 390-397.
34. Leav BA, Blair B, Leney M, Knauber M, Reilly C, et al. (2010) Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28: 965-969.
35. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197-205.
36. Hussack G, Tanha J, (2010) Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives. Toxins (Basel) 2: 998-1018.
37. Ananthakrishnan AN, (2011) Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 8: 17-26.
38. Planche T, Wilcox M, (2011) Reference assays for Clostridium difficile infection: one or two gold standards? J Clin Pathol 64: 1-5.
39. Egerer M, Giesemann T, Herrmann C, Aktories K, (2009) Autocatalytic processing of Clostridium difficile toxin B. Binding of inositol hexakisphosphate. J Biol Chem 284: 3389-3395.
40. Egerer M, Giesemann T, Jank T, Satchell KJ, Aktories K, (2007) Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem 282: 25314-25321.
41. Satchell KJ, (2007) MARTX, multifunctional autoprocessing repeats-in-toxin toxins. Infect Immun 75: 5079-5084.
42. Puri AW, Lupardus PJ, Deu E, Albrow VE, Garcia KC, et al. (2010) Rational design of inhibitors and activity-based probes targeting Clostridium difficile virulence factor TcdB. Chem Biol 17: 1201-1211.
43. Savidge TC, Urvil P, Oezguen N, Ali K, Choudhury A, et al. (2011) Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med 17: 1136-1141.
44. Lanis JM, Barua S, Ballard JD, (2010) Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog 6: e1001061.
45. Lanis JM, Hightower LD, Shen A, Ballard JD, (2012) TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol 84: 66-76.
46. Wilkins TD, Lyerly DM, (2003) Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 41: 531-534.
47. Bouvet PJ, Popoff MR, (2008) Genetic relatedness of Clostridium difficile isolates from various origins determined by triple-locus sequence analysis based on toxin regulatory genes tcdC, tcdR, and cdtR. J Clin Microbiol 46: 3703-3713.
48. Florin I, Thelestam M, (1981) Intoxication of cultured human lung fibroblasts with Clostridium difficile toxin. Infect Immun 33: 67-74.
49. Kushnaryov VM, Redlich PN, Sedmak JJ, Lyerly DM, Wilkins TD, et al. (1992) Cytotoxicity of Clostridium difficile toxin A for human colonic and pancreatic carcinoma cell lines. Cancer Res 52: 5096-5099.
50. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
51. Chung WB, Backstrom LR, McDonald J, Collins MT, (1993) The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) colorimetric assay for the quantitation of Actinobacillus pleuropneumoniae cytotoxin. Can J Vet Res 57: 159-165.
52. Yang G, Zhou B, Wang J, He X, Sun X, et al. (2008) Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol 8: 192.
53. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP, (1996) Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. Gut 38: 337-347.
54. Mullan N, Hughes KR, Mahida YR, (2011) Primary human colonic myofibroblasts are resistant to Clostridium difficile toxin A-induced, but not toxin B-induced, cell death. Infect Immun 79: 1623-1630.
55. Rothman SW, (1986) Technique for measuring 50% end points in cytotoxicity assays for Clostridium difficile toxins. J Clin Pathol 39: 672-676.
56. Rothman SW, Brown JE, Diecidue A, Foret DA, (1984) Differential cytotoxic effects of toxins A and B isolated from Clostridium difficile. Infect Immun 46: 324-331.
57. Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman LG, et al. (2003) Expression of Clostridium difficile toxins A and B and their sigma factor TcdD is controlled by temperature. Infect Immun 71: 1784-1793.
58. Hammond GA, Johnson JL, (1995) The toxigenic element of Clostridium difficile strain VPI 10463. Microb Pathog 19: 203-213.
59. MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, et al. (2006) Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44: 2147-2152.
60. Dupuy B, Govind R, Antunes A, Matamouros S, (2008) Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 57: 685-689.
61. Curry SR, Marsh JW, Muto CA, O'Leary MM, Pasculle AW, et al. (2007) tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45: 215-221.
62. Wolff D, Bruning T, Gerritzen A, (2009) Rapid detection of the Clostridium difficile ribotype 027 tcdC gene frame shift mutation at position 117 by real-time PCR and melt curve analysis. Eur J Clin Microbiol Infect Dis 28: 959-962.
63. Matamouros S, England P, Dupuy B, (2007) Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64: 1274-1288.
64. Murray R, Boyd D, Levett PN, Mulvey MR, Alfa MJ, (2009) Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis 9: 103.
65. Verdoorn BP, Orenstein R, Rosenblatt JE, Sloan LM, Schleck CD, et al. (2010) High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagn Microbiol Infect Dis 66: 24-28.
66. Goldenberg SD, French GL, (2011) Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect 62: 355-362.
67. Cloud J, Noddin L, Pressman A, Hu M, Kelly C, (2009) Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 7: 868-873 e862.
68. Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M, et al. (2010) Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin Infect Dis 50: e77-81.
69. Sirard S, Valiquette L, Fortier LC, (2011) Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 49: 4040-4046.
70. Underwood S, Guan S, Vijayasubhash V, Baines SD, Graham L, et al. (2009) Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 191: 7296-7305.
71. Saujet L, Monot M, Dupuy B, Soutourina O, Martin-Verstraete I, (2011) The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile. J Bacteriol 193: 3186-3196.
72. Dineen SS, Villapakkam AC, Nordman JT, Sonenshein AL, (2007) Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol 66: 206-219.
73. Dineen SS, McBride SM, Sonenshein AL, (2010) Integration of metabolism and virulence by Clostridium difficile CodY. J Bacteriol 192: 5350-5362.
74. Yamakawa K, Karasawa T, Ikoma S, Nakamura S, (1996) Enhancement of Clostridium difficile toxin production in biotin-limited conditions. J Med Microbiol 44: 111-114.
75. Yamakawa K, Karasawa T, Ohta T, Hayashi H, Nakamura S, (1998) Inhibition of enhanced toxin production by Clostridium difficile in biotin-limited conditions. J Med Microbiol 47: 767-771.
76. Karlsson S, Burman LG, Akerlund T, (2008) Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology 154: 3430-3436.
77. Karlsson S, Burman LG, Akerlund T, (1999) Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145 (Pt 7): 1683-1693.
78. Antunes A, Martin-Verstraete I, Dupuy B, (2011) CcpA-mediated repression of Clostridium difficile toxin gene expression. Mol Microbiol 79: 882-899.
79. Dupuy B, Sonenshein AL, (1998) Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol 27: 107-120.
80. Osgood DP, Wood NP, Sperry JF, (1993) Nutritional aspects of cytotoxin production by Clostridium difficile. Appl Environ Microbiol 59: 3985-3988.
81. Karasawa T, Maegawa T, Nojiri T, Yamakawa K, Nakamura S, (1997) Effect of arginine on toxin production by Clostridium difficile in defined medium. Microbiol Immunol 41: 581-585.
82. Maegawa T, Karasawa T, Ohta T, Wang X, Kato H, et al. (2002) Linkage between toxin production and purine biosynthesis in Clostridium difficile. J Med Microbiol 51: 34-41.
83. Haslam SC, Ketley JM, Mitchell TJ, Stephen J, Burdon DW, et al. (1986) Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol 21: 293-297.
84. Karasawa T, Ikoma S, Yamakawa K, Nakamura S, (1995) A defined growth medium for Clostridium difficile. Microbiology 141 (Pt 2): 371-375.
85. Goldblith SA, Wick EL (1961) Analysis of human fecal components and study of methods for their recovery in space systems. Wright-Patterson Air Force Base, OH: Aeronautical Systems Division. ix, 57 pp.
86. Wilson KH, Freter R, (1986) Interaction of Clostridium difficile and Escherichia coli with microfloras in continuous-flow cultures and gnotobiotic mice. Infect Immun 54: 354-358.
87. Wilson KH, Perini F, (1988) Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora. Infect Immun 56: 2610-2614.
88. Wilson KH, Sheagren JN, Freter R, Weatherbee L, Lyerly D, (1986) Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis 153: 547-551.
89. Ryder AB, Huang Y, Li H, Zheng M, Wang X, et al. (2010) Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system. J Clin Microbiol 48: 4129-4134.
90. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, et al. (1995) Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 95: 2004-2011.
91. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, et al. (2010) Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192: 4904-4911.
92. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M, (1998) A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36: 2240-2247.
93. Rupnik M, (2010) Clostridium difficile toxinotyping. Methods Mol Biol 646: 67-76.